Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Arginine N-succinyltransferase is the primary enzyme in the arginine succinyltransferase (AST) pathway, a major catabolic route for L-arginine in bacteria such as Pseudomonas aeruginosa and Escherichia coli (UniProt P09050, P0A9M0). It catalyzes the transfer of a succinyl group from succinyl-CoA to the alpha-amino group of L-arginine, producing N2-succinyl-L-arginine (EC 2.3.1.109). This metabolic process allows the bacteria to utilize arginine as a source of carbon, nitrogen, and energy, which is vital for survival in diverse environments (PubMed: 10411748). In pathogens like P. aeruginosa, the AST pathway is involved in the regulation of virulence and adaptation to the host environment. Although there are currently no clinical drugs targeting this enzyme, it is considered a viable target for novel antibacterial strategies due to its absence in human metabolic pathways. Inhibiting this enzyme could potentially disrupt bacterial growth and reduce the fitness of the pathogen during infection.
Inhibition of the arginine succinyltransferase pathway to disrupt bacterial nitrogen utilization and growth.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Arginine N-succinyltransferase (AST).